The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease
The flexible dosage form combined with the increased maintenance of a therapeutic dextensoprazole concentration in plasma with a modified release and prolonged inhibition of acid secretion after administration of the drug suggests that dexlansoprozole has several advantages for patients with acid-de...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-04-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2451 |
| _version_ | 1827962157490241536 |
|---|---|
| author | N. V. Topchiy A. S. Toporkov |
| author_facet | N. V. Topchiy A. S. Toporkov |
| author_sort | N. V. Topchiy |
| collection | DOAJ |
| description | The flexible dosage form combined with the increased maintenance of a therapeutic dextensoprazole concentration in plasma with a modified release and prolonged inhibition of acid secretion after administration of the drug suggests that dexlansoprozole has several advantages for patients with acid-dependent diseases. The pharmacokinetic profile of dexlansoprazole is characterized by two Tmax peaks in 1–2 and 4–5 hours after administrating the drug and ensures a stable concentration of it in the blood. The efficacy of dexlansoprozole in the treatment of various forms of gastroesophageal reflux disease has been confirmed by several randomized controlled clinical trials. |
| first_indexed | 2024-04-09T16:38:01Z |
| format | Article |
| id | doaj.art-a5aa7befacc14eea900d40d937ea58bb |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:38:01Z |
| publishDate | 2018-04-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-a5aa7befacc14eea900d40d937ea58bb2023-04-23T06:56:50ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-04-0103324110.21518/2079-701X-2018-3-32-412425The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux diseaseN. V. Topchiy0A. S. Toporkov1Russian Medical Academy of Continuing Postgraduate Education; Association of General Practitioners (Family Physicians) of the Russian Federation Russian Gastroenterological AssociationRussian Medical Academy of Continuing Postgraduate Education; Association of General Practitioners (Family Physicians) of the Russian Federation Russian Gastroenterological AssociationThe flexible dosage form combined with the increased maintenance of a therapeutic dextensoprazole concentration in plasma with a modified release and prolonged inhibition of acid secretion after administration of the drug suggests that dexlansoprozole has several advantages for patients with acid-dependent diseases. The pharmacokinetic profile of dexlansoprazole is characterized by two Tmax peaks in 1–2 and 4–5 hours after administrating the drug and ensures a stable concentration of it in the blood. The efficacy of dexlansoprozole in the treatment of various forms of gastroesophageal reflux disease has been confirmed by several randomized controlled clinical trials.https://www.med-sovet.pro/jour/article/view/2451gastroesophageal reflux diseaseproton pump inhibitorspatient adherence to therapydexlansoprozole |
| spellingShingle | N. V. Topchiy A. S. Toporkov The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease Медицинский совет gastroesophageal reflux disease proton pump inhibitors patient adherence to therapy dexlansoprozole |
| title | The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease |
| title_full | The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease |
| title_fullStr | The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease |
| title_full_unstemmed | The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease |
| title_short | The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease |
| title_sort | strategy for choosing a new generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease |
| topic | gastroesophageal reflux disease proton pump inhibitors patient adherence to therapy dexlansoprozole |
| url | https://www.med-sovet.pro/jour/article/view/2451 |
| work_keys_str_mv | AT nvtopchiy thestrategyforchoosinganewgenerationprotonpumpinhibitordexlansoprazoleinthetreatmentofgastroesophagealrefluxdisease AT astoporkov thestrategyforchoosinganewgenerationprotonpumpinhibitordexlansoprazoleinthetreatmentofgastroesophagealrefluxdisease AT nvtopchiy strategyforchoosinganewgenerationprotonpumpinhibitordexlansoprazoleinthetreatmentofgastroesophagealrefluxdisease AT astoporkov strategyforchoosinganewgenerationprotonpumpinhibitordexlansoprazoleinthetreatmentofgastroesophagealrefluxdisease |